{"entity":{"id":"at-1965","kind":"drug","name":"AT-1965","aka":["AT1965"],"tldr":"AT-1965 is an experimental small molecule in liposomal formulation from Alyssum Therapeutics, in phase 1 trials for advanced solid tumours, sarcoma and endometrial and vulvovaginal cancers and other cancers.","summary":"AT-1965 (AT1965) is a small molecule in liposomal formulation (intravenous) from Alyssum Therapeutics. Inhibits CMTR2, which labels RNA as 'self', so cancer-cell RNA looks viral, triggering an IFIT-driven antiviral response and recruiting B cells against the tumour. Its furthest stage is phase 1, for advanced solid tumours, sarcoma, endometrial and vulvovaginal cancers and breast cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 recruiting since Feb 2024 (registry). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Alyssum Therapeutics: alyssumtx.com","url":"https://www.alyssumtx.com/"},{"label":"Alyssum Therapeutics: alyssumtx.com","url":"https://www.alyssumtx.com/our-science"},{"label":"Alyssum Therapeutics: alyssumtx.com","url":"https://www.alyssumtx.com/patients"},{"label":"Alyssum Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06234098"},{"label":"ClinicalTrials.gov: trials of AT-1965","url":"https://clinicaltrials.gov/search?intr=AT-1965"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cmtr2"],"drugs":[],"companies":["alyssum-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06234098"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AT-1965","modality":"Small molecule in liposomal formulation (intravenous)","mechanism":"Inhibits CMTR2, which labels RNA as 'self', so cancer-cell RNA looks viral, triggering an IFIT-driven antiviral response and recruiting B cells against the tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/at-1965/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/"}],"company":[{"id":"alyssum-therapeutics","kind":"company","name":"Alyssum Therapeutics","route":"/companies/alyssum-therapeutics/"}],"trial":[{"id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/"}]}}